These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 30423939)

  • 1. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
    Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
    Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
    Dessalew N; Singh SK
    Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.
    Lan P; Chen WN; Chen WM
    Eur J Med Chem; 2011 Jan; 46(1):77-94. PubMed ID: 21093113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
    He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
    Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
    Chaube U; Bhatt H
    Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
    Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of novel dopamine D
    Zhang C; Li Q; Meng L; Ren Y
    J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
    Zhu J; Ke K; Xu L; Jin J
    J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of Structural Requirements of N-Substituted Tetrahydro-β-Carboline Imidazolium Salt Derivatives Using in Silico Approaches for Designing MEK-1 Inhibitors.
    Liang J; Wang M; Li X; He X; Cao C; Meng F
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28629184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.